Tactile Medical Appoints Sherri Ferstler as Senior Vice President of Sales
18 Juillet 2023 - 2:00PM
Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq:
TCMD), a medical technology company providing therapies for people
with chronic disorders, today announced the appointment of Sherri
Ferstler to the position of Senior Vice President of Sales,
effective July 31, 2023. Ms. Ferstler will succeed Eric Pauls, who
will be resigning from the Company, effective July 28, 2023.
“Sherri is a strategic leader with over 25 years
of experience in the healthcare industry and a successful history
of developing and leading high-performance teams at scale,” said
Dan Reuvers, President and Chief Executive Officer of Tactile
Medical. “Sherri brings extensive executive sales leadership
experience, most recently within Johnson & Johnson Vision,
where she led a team of over 325. She’s proven herself as a strong
developer of teams that deliver high-growth results on both the top
and bottom-line. She’s led multiple successful product launches,
resourcefully used data to expand field-productivity and proven
herself as a coach at multiple levels. Adding Sherri further
enriches our executive leadership team, our ability to build and
operate at scale, and our ability to lead change and expand
productivity.”
Mr. Reuvers continued: “I also want to thank
Eric for his contributions to Tactile Medical and the patients with
chronic conditions that we serve.”
Prior to joining Tactile Medical, Ms. Ferstler
served as Vice President Sales, North America for Johnson &
Johnson Vision since 2016. In this position, Ms. Ferstler led the
field & inside sales teams, strategic accounts & training
functions selling Acuvue brand contact lenses across multiple
channels.
Ms. Ferstler began her career in 1992 with
Parke-Davis Pharmaceuticals where she served in a variety of sales,
sales management and training and development roles. She joined
Pfizer in 2000, serving as a district sales manager for all branded
pharmaceutical products until 2003, then as Director of Division
Operations and as a regional manager for Pfizer’s Urology and
Respiratory product portfolios. From 2007 to 2016, Ms. Ferstler led
regional and national sales teams for Endo Pharmaceuticals, Bayer
Diabetes Care and Mylan Pharmaceuticals. Ms. Ferstler holds
Bachelor of Arts in Psychology from the State University of New
York College at Buffalo.
About Tactile Systems Technology, Inc. (DBA Tactile
Medical)
Tactile Medical is a leader in developing and
marketing at-home therapies for people suffering from underserved,
chronic conditions including lymphedema, lipedema, chronic venous
insufficiency and chronic pulmonary disease by helping them live
better and care for themselves at home. Tactile Medical
collaborates with clinicians to expand clinical evidence, raise
awareness, increase access to care, reduce overall healthcare costs
and improve the quality of life for tens of thousands of patients
each year.
Legal Notice Regarding Forward-Looking
Statements
This release contains forward-looking
statements. Forward-looking statements are generally identifiable
by the use of words like “may,” “will,” “should,” “could,”
“expect,” “anticipate,” “estimate,” “believe,” “intend,”
“continue,” “confident,” “outlook,” “guidance,” “project,” “goals,”
“look forward,” “poised,” “designed,” “plan,” “return,” “focused,”
“prospects” or “remain” or the negative of these words or other
variations on these words or comparable terminology. The reader is
cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous factors and
uncertainties outside of the Company’s control that can make such
statements untrue, including, but not limited to, the impacts of
inflation, rising interest rates or a recession; the adequacy of
the Company’s liquidity to pursue its business objectives; the
Company’s ability to obtain reimbursement from third-party payers
for its products; adverse economic conditions or intense
competition; price increases for supplies and components; wage and
component price inflation; loss of a key supplier; entry of new
competitors and products; compliance with and changes in federal,
state and local government regulation; loss or retirement of key
executives, including prior to identifying a successor;
technological obsolescence of the Company’s products; technical
problems with the Company’s research and products; the Company’s
ability to expand its business through strategic acquisitions; the
Company’s ability to integrate acquisitions and related businesses;
the impacts of the COVID-19 pandemic on the Company’s business,
financial condition and results of operations, and the Company’s
inability to mitigate such impacts; the effects of current and
future U.S. and foreign trade policy and tariff actions; or the
inability to carry out research, development and commercialization
plans. In addition, other factors that could cause actual results
to differ materially are discussed in the Company’s filings with
the SEC. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company undertakes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Investor Inquiries:
Mike Piccinino, CFA
ICR Westwicke
443-213-0500
investorrelations@tactilemedical.com
Tactile Systems Technology (NASDAQ:TCMD)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Tactile Systems Technology (NASDAQ:TCMD)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024